Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $3.37 billion. The enterprise value is $2.80 billion.
Important Dates
The last earnings date was Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 77.28 million shares outstanding. The number of shares has increased by 4.00% in one year.
| Current Share Class | 77.28M |
| Shares Outstanding | 77.28M |
| Shares Change (YoY) | +4.00% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 103.31% |
| Float | 71.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 446.75 |
| Forward PS | n/a |
| PB Ratio | 6.00 |
| P/TBV Ratio | 5.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 373.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.52 |
| Quick Ratio | 12.08 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.14% and return on invested capital (ROIC) is -30.97%.
| Return on Equity (ROE) | -45.14% |
| Return on Assets (ROA) | -29.51% |
| Return on Invested Capital (ROIC) | -30.97% |
| Return on Capital Employed (ROCE) | -59.84% |
| Revenue Per Employee | $22,936 |
| Profits Per Employee | -$936,801 |
| Employee Count | 327 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.85% in the last 52 weeks. The beta is 1.03, so XENE's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +2.85% |
| 50-Day Moving Average | 41.39 |
| 200-Day Moving Average | 36.01 |
| Relative Strength Index (RSI) | 54.77 |
| Average Volume (20 Days) | 764,956 |
Short Selling Information
The latest short interest is 6.04 million, so 7.82% of the outstanding shares have been sold short.
| Short Interest | 6.04M |
| Short Previous Month | 5.79M |
| Short % of Shares Out | 7.82% |
| Short % of Float | 8.42% |
| Short Ratio (days to cover) | 7.69 |
Income Statement
In the last 12 months, XENE had revenue of $7.50 million and -$306.33 million in losses. Loss per share was -$3.89.
| Revenue | 7.50M |
| Gross Profit | -265.21M |
| Operating Income | -340.78M |
| Pretax Income | -309.70M |
| Net Income | -306.33M |
| EBITDA | -338.18M |
| EBIT | -340.78M |
| Loss Per Share | -$3.89 |
Full Income StatementBalance Sheet
The company has $462.27 million in cash and $8.33 million in debt, giving a net cash position of $546.93 million or $7.08 per share.
| Cash & Cash Equivalents | 462.27M |
| Total Debt | 8.33M |
| Net Cash | 546.93M |
| Net Cash Per Share | $7.08 |
| Equity (Book Value) | 559.51M |
| Book Value Per Share | 7.26 |
| Working Capital | 441.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$252.02 million and capital expenditures -$1.26 million, giving a free cash flow of -$253.29 million.
| Operating Cash Flow | -252.02M |
| Capital Expenditures | -1.26M |
| Free Cash Flow | -253.29M |
| FCF Per Share | -$3.28 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,543.73% |
| Pretax Margin | -4,129.39% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.00% |
| Shareholder Yield | -4.00% |
| Earnings Yield | -9.14% |
| FCF Yield | -7.56% |
Dividend DetailsAnalyst Forecast
The average price target for XENE is $53.55, which is 22.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $53.55 |
| Price Target Difference | 22.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 31.35 and a Piotroski F-Score of 1.
| Altman Z-Score | 31.35 |
| Piotroski F-Score | 1 |